Fact CheckerSign in

NCT07192913Not yet recruitingPhase 2

Glymphatic Function TMS Study

Investigating the Impact of Transcranial Magnetic Stimulation (TMS) on Amyloid and Tau Clearance Via Glymphatic Function in Prodromal Alzheimer's Disease

Source: ClinicalTrials.gov · Last updated 17 Dec 2025

Brief summary (registry, in English)

The purpose of this study is to use transcranial magnetic stimulation (TMS) in older adults to impact the glymphatic system. The glymphatic system is a brain-wide clearance pathway that plays a crucial role in removing dysfunctional proteins in Alzheimer's disease. This project aims to investigate if TMS can help glymphatic function and reduce levels of these proteins in those with mild cognitive impairment.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
First submitted
12 Sept 2025
Start date
1 Jan 2026
Primary completion date
31 Jul 2026
Lead sponsor
University of Arizona
NCT number
NCT07192913

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 20
  • From 1 Jan 2026 to the primary completion date, 31 Jul 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Telephone Interview for cognitive impairment (TICS) score
  • Other neurological disorders (e.g., stroke, head injuries, or multiple sclerosis)
  • Psychiatric disorder (except stable late-life depression due to its high prevalence in MCI individuals)
  • Current cancer treatment or other comorbid/unstable medical conditions that might independently affect cognitive function

Other

  • Contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI)
  • Reported sudden or steep decline of cognitive performance

Who the study is looking for

  • Individuals with mild cognitive impairment (MCI Group)
  • Age 18-85 years
  • MCI subjective criteria: self- or informant-reported cognitive complaint
  • Objective cognitive impairment supported by one of the following measures of general cognitive function: (a) classified as MCI via the NACC-UDS 3.0 neuropsychological battery using the typical neuropsychological criteria for MCI diagnosis (1 score on any test at least1.5 SD below the mean); or (b) classified as MCI via the NACC-UDS 3.0 neuropsychological battery using the Jak/Bondi neuropsychological criteria for MCI diagnosis(2 scores at least 1 SD below the mean in one domain, or 3 scores at least 1SD below the mean across domains)
  • Right-handed
  • English speaking
  • Able to attend daily intervention and outcome measurements for \~15 days over a 6 month period.
  • Not enrolled in another interventional study within 6 months prior to beginning this study

Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.